CT P25Alternative Names: Influenza vaccine - Celltrion
Latest Information Update: 16 Mar 2016
At a glance
- Originator Celltrion
- Class Vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Influenza virus infections
Most Recent Events
- 16 Mar 2016 Preclinical development is ongoing in South Korea (Celltrion pipeline, March 2016)
- 30 Sep 2012 Preclinical trials in Influenza virus infections in South Korea (Parenteral) before September 2102